|Delayed - 10/25 02:13:25 pm|
Innocan Pharma Corporation Enters into Research and License Agreement with Ramot08/18/2021 | 07:12am
Innocan Pharma Corporation announced that, following the early indications of its CBD Loaded Exosomes platform (CLX), the Company has issued a notice to Ramot, the Technology Transfer Company of Tel Aviv University (TAU), declaring the Company's intention to exercise its option to enter into a full Research and License Agreement with Ramot (the "Agreement"). It is expected that the agreement, once entered, will grant InnoCan a worldwide exclusive license to advance and to commercialize the products that will be developed from the technology. Given the meaningful achievements in the development of the CLX, Innocan has concluded to execute its option based on the agreement with Ramot, and to step up this deep and meaningful co-operation which serves as a significant milestone in the Company's strategic commercialization strategy.
© S&P Capital IQ 2021
All news about INNOCAN PHARMA CORPORATION